Quest Diagnostics (DGX) EBITDA (2016 - 2025)
Historic EBITDA for Quest Diagnostics (DGX) over the last 17 years, with Q3 2025 value amounting to $386.0 million.
- Quest Diagnostics' EBITDA rose 1696.97% to $386.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 2228.43%. This contributed to the annual value of $1.3 billion for FY2024, which is 665.61% up from last year.
- As of Q3 2025, Quest Diagnostics' EBITDA stood at $386.0 million, which was up 1696.97% from $438.0 million recorded in Q2 2025.
- Over the past 5 years, Quest Diagnostics' EBITDA peaked at $660.0 million during Q1 2021, and registered a low of $135.0 million during Q4 2022.
- Moreover, its 5-year median value for EBITDA was $361.0 million (2024), whereas its average is $399.3 million.
- Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 27714.29% in 2021, then crashed by 7481.34% in 2022.
- Quest Diagnostics' EBITDA (Quarter) stood at $536.0 million in 2021, then tumbled by 74.81% to $135.0 million in 2022, then surged by 97.78% to $267.0 million in 2023, then skyrocketed by 35.21% to $361.0 million in 2024, then grew by 6.93% to $386.0 million in 2025.
- Its last three reported values are $386.0 million in Q3 2025, $438.0 million for Q2 2025, and $346.0 million during Q1 2025.